X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with JUBILANT LIFE SCIENCES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs JUBILANT LIFE SCIENCES - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. JUBILANT LIFE SCIENCES FRESENIUS KABI ONCO./
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 22.1 27.1 81.7% View Chart
P/BV x 3.1 5.6 56.0% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 FRESENIUS KABI ONCO.   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
JUBILANT LIFE SCIENCES
Mar-14
FRESENIUS KABI ONCO./
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs176187 94.2%   
Low Rs7965 120.6%   
Sales per share (Unadj.) Rs37.7364.3 10.3%  
Earnings per share (Unadj.) Rs5.16.8 74.4%  
Cash flow per share (Unadj.) Rs6.724.5 27.4%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %02.4 0.0%  
Book value per share (Unadj.) Rs42.5164.9 25.8%  
Shares outstanding (eoy) m158.23159.28 99.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 976.8%   
Avg P/E ratio x25.018.4 135.8%  
P/CF ratio (eoy) x18.95.1 368.2%  
Price / Book Value ratio x3.00.8 391.6%  
Dividend payout %043.8 0.0%   
Avg Mkt Cap Rs m20,13520,061 100.4%   
No. of employees `0001.26.2 18.6%   
Total wages/salary Rs m70311,052 6.4%   
Avg. sales/employee Rs Th5,176.29,383.0 55.2%   
Avg. wages/employee Rs Th610.41,786.9 34.2%   
Avg. net profit/employee Rs Th699.6176.3 396.8%   
INCOME DATA
Net Sales Rs m5,96358,034 10.3%  
Other income Rs m18191 9.4%   
Total revenues Rs m5,98158,224 10.3%   
Gross profit Rs m1,4305,786 24.7%  
Depreciation Rs m2582,812 9.2%   
Interest Rs m-263,237 -0.8%   
Profit before tax Rs m1,216-72 -1,686.8%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-682,145 -3.2%   
Tax Rs m342696 49.1%   
Profit after tax Rs m8061,090 73.9%  
Gross profit margin %24.010.0 240.5%  
Effective tax rate %28.1-965.9 -2.9%   
Net profit margin %13.51.9 719.3%  
BALANCE SHEET DATA
Current assets Rs m5,10229,280 17.4%   
Current liabilities Rs m2,38538,912 6.1%   
Net working cap to sales %45.6-16.6 -274.5%  
Current ratio x2.10.8 284.2%  
Inventory Days Days15084 177.8%  
Debtors Days Days11351 223.5%  
Net fixed assets Rs m5,14855,712 9.2%   
Share capital Rs m158155 102.4%   
"Free" reserves Rs m6,55620,968 31.3%   
Net worth Rs m6,73226,265 25.6%   
Long term debt Rs m95217,169 5.5%   
Total assets Rs m10,38888,606 11.7%  
Interest coverage x-45.81.0 -4,682.0%   
Debt to equity ratio x0.10.7 21.6%  
Sales to assets ratio x0.60.7 87.6%   
Return on assets %7.54.9 153.7%  
Return on equity %12.04.2 288.4%  
Return on capital %14.611.6 126.2%  
Exports to sales %74.537.8 197.0%   
Imports to sales %24.816.5 150.3%   
Exports (fob) Rs m4,44121,933 20.2%   
Imports (cif) Rs m1,4779,567 15.4%   
Fx inflow Rs m5,29822,004 24.1%   
Fx outflow Rs m1,77211,749 15.1%   
Net fx Rs m3,52510,255 34.4%   
CASH FLOW
From Operations Rs m1,2748,026 15.9%  
From Investments Rs m-1,204-1,744 69.0%  
From Financial Activity Rs m-196-4,447 4.4%  
Net Cashflow Rs m-1261,834 -6.9%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 81.0 3.5 2,314.3%  
Indian inst/Mut Fund % 0.3 8.7 3.4%  
FIIs % 9.6 21.2 45.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.1 43.1%  
Shareholders   42,599 23,815 178.9%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Losses; Capital Goods Sector Down 1.7%(11:30 am)

Indian share markets are presently trading on a negative note. Sectoral indices are trading in the red with stocks in the capital goods sector and metal sector witnessing maximum selling pressure.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS